Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Protein Expression and Purification
|
June 25, 2003
Purification and characterization of recombinant Streptomyces griseus aminopeptidase
Sally Xueying Ni, Douglas Cossar, Adrian Man, et al.
Cancers
|
January 10, 2026
Tumor-Immune Cell Crosstalk Drives Immune Cell Reprogramming Towards a Pro-Tumor Proliferative State Involving STAT3 Activation
Karen Norek, Jacob Kennard, Kenneth Fuh, et al.
Atherosclerosis
|
May 24, 2016
Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57]
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Biochemical and Biophysical Research Communications
|
June 11, 2016
RVX-297- a novel BD2 selective inhibitor of BET bromodomains
Olesya A Kharenko, Emily M Gesner, Reena G Patel, et al.
Atherosclerosis
|
February 13, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Data in Brief
|
August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
Sylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Molecular Pharmacology
|
October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
Ravi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Rahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2015
Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design
Bryan C Duffy, Shuang Liu, Gregory S Martin, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Protein Expression and Purification
|
June 25, 2003
Purification and characterization of recombinant Streptomyces griseus aminopeptidase
Sally Xueying Ni, Douglas Cossar, Adrian Man, et al.
Cancers
|
January 10, 2026
Tumor-Immune Cell Crosstalk Drives Immune Cell Reprogramming Towards a Pro-Tumor Proliferative State Involving STAT3 Activation
Karen Norek, Jacob Kennard, Kenneth Fuh, et al.
Atherosclerosis
|
May 24, 2016
Corrigendum to "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease" [Atherosclerosis 247 (2016) 48-57]
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Biochemical and Biophysical Research Communications
|
June 11, 2016
RVX-297- a novel BD2 selective inhibitor of BET bromodomains
Olesya A Kharenko, Emily M Gesner, Reena G Patel, et al.
Atherosclerosis
|
February 13, 2016
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham, Sylwia Wasiak, Laura M Tsujikawa, et al.
Data in Brief
|
August 30, 2016
Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes
Sylwia Wasiak, Dean Gilham, Laura M Tsujikawa, et al.
Molecular Pharmacology
|
October 5, 2017
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
Ravi Jahagirdar, Sarah Attwell, Suzana Marusic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Rahul R Aggarwal, Michael T Schweizer, David M Nanus, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 30, 2015
Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design
Bryan C Duffy, Shuang Liu, Gregory S Martin, et al.
Page
of 1